Methods of treating a tauopathy
AssigneeiPierian, Inc.
InventorsIrene GRISWOLD-PRENNER, Nancy E. STAGLIANO, Vu Cao DANG
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods of treating a tauopathy, involving administering an anti-Tau antibody. The present disclosure also provides anti-Tau antibodies, and formulations comprising same, for use in the methods.
Claims28
An isolated nucleic acid comprising a nucleotide sequence encoding light chain variable region complementarity-determining regions (CDRs) 1, 2, and 3 of a humanized antibody that specifically binds an epitope within the N-terminal portion of a human Tau polypeptide, wherein the:
- (i) VL CDR1 comprises the amino acid sequence of SEQ ID NO:1;
- (ii) VL CDR2 comprises the amino acid sequence of SEQ ID NO:2;
- and
- (iii) VL CDR3 comprises the amino acid sequence of SEQ ID NO:3.
An isolated nucleic acid comprising a nucleotide sequence encoding heavy chain variable region complementarity-determining regions (CDRs) 1, 2, and 3 of a humanized antibody that specifically binds an epitope within the N-terminal portion of a human Tau polypeptide, wherein the:
- (i) VH CDR1 comprises the amino acid sequence of SEQ ID NO:4;
- (ii) VH CDR2 comprises the amino acid sequence of SEQ ID NO:5;
- and
- (iii) VH CDR3 comprises the amino acid sequence of SEQ ID NO:6.
An isolated nucleic acid comprising a nucleotide sequence encoding light and heavy chain variable region complementarity-determining regions (CDRs) 1, 2, and 3 of a humanized antibody that specifically binds an epitope within the N-terminal portion of a human Tau polypeptide, wherein the:
- (i) VL CDR1 comprises the amino acid sequence of SEQ ID NO:1;
- (ii) VL CDR2 comprises the amino acid sequence of SEQ ID NO:2;
- (iii) VL CDR3 comprises the amino acid sequence of SEQ ID NO:3;
- (iv) VH CDR1 comprises the amino acid sequence of SEQ ID NO:4;
- (v) VH CDR2 comprises the amino acid sequence of SEQ ID NO:5;
- and
- (vi) VH CDR3 comprises the amino acid sequence of SEQ ID NO:6.
An isolated nucleic acid comprising a nucleotide sequence encoding light chain variable region complementarity-determining regions (CDRs) 1, 2, and 3 of a humanized antibody that specifically binds an epitope within the N-terminal portion of a human Tau polypeptide, wherein the:
- (i) VL CDR1 comprises the amino acid sequence of SEQ ID NO:7;
- (ii) VL CDR2 comprises the amino acid sequence of SEQ ID NO:8;
- and
- (iii) VL CDR3 comprises the amino acid sequence of SEQ ID NO:9.
An isolated nucleic acid comprising a nucleotide sequence encoding heavy chain variable region complementarity-determining regions (CDRs) 1, 2, and 3 of a humanized antibody that specifically binds an epitope within the N-terminal portion of a human Tau polypeptide, wherein the:
- (i) VH CDR1 comprises the amino acid sequence of SEQ ID NO:10;
- (ii) VH CDR2 comprises the amino acid sequence of SEQ ID NO:11;
- and
- (iii) VH CDR3 comprises the amino acid sequence of SEQ ID NO:12.
An isolated nucleic acid comprising a nucleotide sequence encoding light and heavy chain variable region complementarity-determining regions (CDRs) 1, 2, and 3 of a humanized antibody that specifically binds an epitope within the N-terminal portion of a human Tau polypeptide, wherein the:
- (i) VL CDR1 comprises the amino acid sequence of SEQ ID NO:7;
- (ii) VL CDR2 comprises the amino acid sequence of SEQ ID NO:8;
- (iii) VL CDR3 comprises the amino acid sequence of SEQ ID NO:9;
- (iv) VH CDR1 comprises the amino acid sequence of SEQ ID NO:10;
- (v) VH CDR2 comprises the amino acid sequence of SEQ ID NO:11;
- and
- (vi) VH CDR3 comprises the amino acid sequence of SEQ ID NO:12.
An isolated nucleic acid comprising a nucleotide sequence encoding a VH variant and/or a Vk variant, wherein:
- a) the VH variant comprises the amino acid sequence depicted in FIG. 9 (SEQ ID NO:36) and/or the Vk variant comprises the amino acid sequence depicted in FIG. 13 (SEQ ID NO:40);
- b) the VH variant comprises the amino acid sequence depicted in FIG. 9 (SEQ ID NO:36);
- and/or the Vk variant comprises the amino acid sequence depicted in FIG. 14 (SEQ ID NO:41);
- c) the VH variant comprises the amino acid sequence depicted in FIG. 9 (SEQ ID NO:36);
- and/or the Vk variant comprises the amino acid sequence depicted in FIG. 15 (SEQ ID NO:42);
- d) the VH variant comprises the amino acid sequence depicted in FIG. 9 (SEQ ID NO:36);
- and/or the Vk variant comprises the amino acid sequence depicted in FIG. 16 (SEQ ID NO:43);
- e) the VH variant comprises the amino acid sequence depicted in FIG. 10 (SEQ ID NO:37);
- and/or the Vk variant comprises the amino acid sequence depicted in FIG. 13 (SEQ ID NO:40);
- f) the VH variant comprises the amino acid sequence depicted in FIG. 10 (SEQ ID NO:37);
- and/or the Vk variant comprises the amino acid sequence depicted in FIG. 14 (SEQ ID NO:41);
- g) the VH variant comprises the amino acid sequence depicted in FIG. 10 (SEQ ID NO:37);
- and/or the Vk variant comprises the amino acid sequence depicted in FIG. 15 (SEQ ID NO:42);
- h) the VH variant comprises the amino acid sequence depicted in FIG. 10 (SEQ ID NO:37);
- and/or the Vk variant comprises the amino acid sequence depicted in FIG. 16 (SEQ ID NO:43);
- i) the VH variant comprises the amino acid sequence depicted in FIG. 11 (SEQ ID NO:38);
- and/or the Vk variant comprising the amino acid sequence depicted in FIG. 13 (SEQ ID NO:40);
- j) the VH variant comprises the amino acid sequence depicted in FIG. 11 (SEQ ID NO:38);
- and/or the Vk variant comprises the amino acid sequence depicted in FIG. 14 (SEQ ID NO:41);
- k) the VH variant comprises the amino acid sequence depicted in FIG. 11 (SEQ ID NO:38);
- and/or the Vk variant comprises the amino acid sequence depicted in FIG. 15 (SEQ ID NO:42);
- l) the VH variant comprises the amino acid sequence depicted in FIG. 11 (SEQ ID NO:38);
- and/or the Vk variant comprises the amino acid sequence depicted in FIG. 16 (SEQ ID NO:43);
- m) the VH variant comprises the amino acid sequence depicted in FIG. 12 (SEQ ID NO:39);
- and/or the Vk variant comprises the amino acid sequence depicted in FIG. 13 (SEQ ID NO:40);
- n) the VH variant comprises the amino acid sequence depicted in FIG. 12 (SEQ ID NO:39);
- and/or the Vk variant comprises the amino acid sequence depicted in FIG. 14 (SEQ ID NO:41);
- o) the VH variant comprises the amino acid sequence depicted in FIG. 12 (SEQ ID NO:39);
- and/or the Vk variant comprises the amino acid sequence depicted in FIG. 15 (SEQ ID NO:42);
- or
- p) the VH variant comprises rising the amino acid sequence depicted in FIG. 12 (SEQ ID NO:39);
- and/or the Vk variant comprising the amino acid sequence depicted in FIG. 16 (SEQ ID NO:43).
A method of monitoring progression of a tauopathy in an individual comprising:
- a) determining a first level of a Tau polypeptide in a biological sample obtained from the individual at a first time point;
- b) determining a second level of a Tau polypeptide in a biological sample obtained from the individual at a second time point;
- and
- c) comparing the second level of Tau with the first level of Tau,
- wherein said determining comprises:
- i) contacting the biological sample with a subject anti-Tau antibody;
- and ii) quantitating binding of the antibody to Tau polypeptide present in the sample.
Dependencies are inferred from the claim text.